Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of subcutaneous mezagitamab in adults with chronic primary immune thrombocytopenia
MOH_2026-03-04_015699Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Mezagitamab with Placebo (2 arms). Planned start Feb 2026; status: not yet recruiting.
02
Drugs
mezagitamab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on MOH_2026-03-04_015699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-04_015699.